Tuesday 16 June 2026

The Pharma Letter Podcast — Episode 26 — CRO sector surges in bio revolution

Biotechnology
Simon Wentworth
24 October 2023
episode26-large-podcast

More on this story...

Pharmaceutical
Two new hires at Asia-Pacific-focused CRO Novotech
13 October 2023
Biotechnology
Singaporean CRO Novotech appoints new chief medical officer
4 October 2023
Pharmaceutical
Growing CDMO appoints new president of Novasep business
19 October 2023
Pharmaceutical
Data show outsourcing growth set to continue in future
1 December 2023




More ones to watch >




Today's issue

Vivoryon’s kidney reset: CEO Frank Weber on the company’s new focus
Biotechnology
Vivoryon’s kidney reset: CEO Frank Weber on the company’s new focus
15 June 2026
Pharmaceutical
Grifols launches Fesilty in USA for rare bleeding disorder
15 June 2026
Biotechnology
Elicio Thera tanks on disappointing Phase II AMPLIFY-7P study
15 June 2026
Pharmaceutical
Two-year data bolster Neurocrine’s Crenessity case in pediatric CAH
15 June 2026
Biotechnology
J&J’s Talvey combo cuts progression risk in earlier myeloma setting
15 June 2026
Pharmaceutical
Pharmstandard to build large-scale complex for production of live vaccines
15 June 2026
Biotechnology
Positive Phase III results for Intellia’s lonvo-z
15 June 2026


Company Spotlight

Avidity Biosciences
A San Diego-based biotechnology company that pioneered muscle-targeted RNA delivery through its proprietary Antibody Oligonucleotide Conjugate platform, Avidity Biosciences was acquired by Novartis in February 2026 for approximately $12 billion.


More Features in Biotechnology

Vivoryon’s kidney reset: CEO Frank Weber on the company’s new focus
15 June 2026
Elicio Thera tanks on disappointing Phase II AMPLIFY-7P study
15 June 2026
J&J’s Talvey combo cuts progression risk in earlier myeloma setting
15 June 2026
Positive Phase III results for Intellia’s lonvo-z
15 June 2026


Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze